Colorcon Launches $50 Million Venture Capital Fund

News
Article

Colorcon Ventures looks to fund promising startups in drug manufacturing, delivery, and supply chain.

Colorcon, a developer of advanced coating systems, modified-release technologies, and functional excipients for pharmaceuticals, announced on Sept. 17, 2019 the establishment of a $50 million venture fund to invest in startup companies developing technologies to advance manufacturing, supply chain, and delivery of pharmaceutical products and services.

Colorcon Ventures is a $50 million venture fund focused on startups that are “strategically relevant to the core Colorcon business,” the company reported in a Sept. 17, 2019 press announcement. The fund will focus on early and mid-stage companies that demonstrate revenue growth; however, it will not invest in companies developing active ingredients or molecules. 

The fund will invest in startups where Colorcon can add subject-matter expertise or commercial relationships, as well as leverage Colorcon’s global reach, industry relationships, and R&D approach, the press statement noted.

Touchdown Ventures, a corporate venture capital firm, will work with Colorcon senior executives to manage the fund.

 “We are excited to launch this venture fund to support the growth of startup companies in the pharmaceutical and healthcare industries,” said Martti Hedman, CEO of Colorcon, in the press release.  “Colorcon has a rich history of innovation and we believe this fund will allow us to continue to serve our customers by partnering with startups.”

“The promise of corporate venture capital is to bring more than just money to the table. A successful corporate investor can generate meaningful value by facilitating commercial relationships with its portfolio companies. We believe that Colorcon Ventures, through close association to the senior executive and business units of Colorcon, is well poised to accomplish this goal,” said David Horowitz, CEO of Touchdown, in the press release.   

Source: Colorcon Ventures

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content